BioMarin Pharmaceutical Inc. completed an all‑cash acquisition of Amicus Therapeutics on April 27, 2026, paying $14.50 per share for a total equity value of roughly $4.8 billion.
The deal was financed with a combination of cash on hand, approximately $3.7 billion in nonconvertible debt, and new senior secured credit facilities totaling $3.4 billion, giving BioMarin a robust balance‑sheet structure to support the integration and future growth.
The acquisition expands BioMarin’s rare‑disease portfolio by adding Galafold (migalastat), the first oral treatment for Fabry disease, and the two‑component therapy Pombiliti (cipaglucosidase alfa‑atga) plus Opfolda (miglustat) for Pompe disease. It also grants U.S. rights to DMX‑200, a Phase 3 candidate for focal segmental glomerulosclerosis.
Galafold is approved in more than 40 countries and provides a convenient oral alternative for patients with amenable galactosidase alpha gene variants. Pombiliti + Opfolda offers a novel approach for adult patients with late‑onset Pompe disease who are not responding to existing enzyme replacement therapy. DMX‑200, a CCR2 inhibitor, is in Phase 3 development and represents a new potential revenue stream for BioMarin’s kidney‑disease pipeline.
Alexander Hardy, President and Chief Executive Officer of BioMarin, stated: "The completion of the Amicus acquisition advances BioMarin's strategy to strengthen and diversify our growth profile while furthering our mission to deliver medicines for people living with rare diseases." He added: "BioMarin's global scale, established commercial infrastructure, and advanced in‑house manufacturing capabilities build on Amicus' legacy and position us to bring Galafold and Pombiliti + Opfolda to more patients around the world." Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, expressed pride in his team and stated: "I am enormously proud of our Amicus team."
The transaction is expected to be accretive to BioMarin's Non‑GAAP diluted earnings per share within the first 12 months after closing, as the company leverages its commercial and manufacturing capabilities to scale the newly acquired products. The addition of Galafold and Pombiliti + Opfolda strengthens BioMarin’s market position in lysosomal storage disorders, while the Phase 3 DMX‑200 candidate diversifies its pipeline into kidney disease, positioning the company for continued growth in high‑need therapeutic areas.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.